Viral haemorrhagic fever: modern approaches for developing bedside rapid diagnostics


Start Date
End Date
IMI2 - Call 8
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
3 316 013
Associated Partners
1 574 000
160 000
Total Cost
5 050 013


Better, faster diagnosis of viral haemorrhagic fevers like Ebola is the ultimate goal of the VHFMoDRAD project. As their name implies, viral haemorrhagic fevers are caused by viruses and a common symptoms is severe bleeding, which often results in death. Examples include Ebola and Marburg as well as dengue and yellow fever. As these diseases have many symptoms in common, it is often hard to deliver a rapid diagnosis, yet in an outbreak setting, this is essential. The aim of VHFMoDRAD is to develop rapid point-of-care (POC) diagnostic tools capable of identifying a number of viral haemorrhagic fevers. The project builds on the work of IMI’s EbolaMoDRAD project, which advanced the development of rapid diagnostics for Ebola. The new tools and methods developed by VHFMoDRAD will be validated in the field. In addition, the project plans to run training courses for professionals in the west African region. It will also transfer the production capacity for the diagnostic tools to a project partner in the region so that the tests can be produced locally. Ultimately, VHFMoDRAD will contribute to better preparedness for outbreaks of viral haemorrhagic fevers, and to capacity building in Africa.

Participants Show participants on map

Universities, research organisations, public bodies, non-profit groups
  • Department of Health, Leeds, United Kingdom
  • Emergency Life Support For Civilian War Victims Ong Onlus, Milan, Italy
  • Folkhalsomyndigheten, Solna, Sweden
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Institut Pasteur De Dakar, Dakar, Senegal
  • Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy
  • Kobenhavns Universitet, Copenhagen, Denmark
  • The University Of Stirling, Stirling, United Kingdom
  • Universite D'Aix Marseille, Marseille, France
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Coris Bioconcept SPRL, Gembloux, Belgium
  • Inserm Transfert SA, Paris, France
  • Rd-Biotech, Besançon, France
Associated partners
  • Cepheid Europe, Maurens Scopont, France
Third parties
  • Biotech Investissement, Besancon, France


Project coordinator